Sagimet Biosciences Inc.
SGMT Nasdaq
SEC CIK 1400118
Follow Sagimet Biosciences
Weekly email: filings, results
Net income
−$19.1M
−48.3% vs same quarter last year
EPS, diluted
−$0.31
+22.5% vs same quarter last year
Operating cash flow
−$12.1M
−19% vs same quarter last year
Operating income
−$21.6M
−50.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$51M |
| FY24 | −$45.6M |
| FY23 | −$27.9M |
| FY22 | −$30.5M |
| FY21 | - |